Key Market Indicator:
F&G: 54
25.478,95 NASDAQ · 49.435,00 DOW · 6.912,45 S&P · 4.967,49 Gold · 63,65 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
© Globe Newswire
09.07.2024
ISIN: FR0004163111
Genfit SA
GNFT
LISTED
EURONEXT
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Article
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) July 9, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et...
Themefolio
Profiler
Peergroup
© PR Newswire
09.07.2024
ISIN: GB00BN4HT335
Indivior PLC
INDV
LISTED
NASDAQ
Indivior Provides Business Update; Conference Call at 8:00 AM U.S. EDT
Article
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). RICHMOND, Va., July 9, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announces a business update encompassing the...
Themefolio
Profiler
Peergroup
© PR Newswire
09.07.2024
ISIN: GB00BN4HT335
Indivior PLC
INDV
LISTED
NASDAQ
Indivior Provides Business Update; Conference Call at 8:00 AM U.S. EDT
Article
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). RICHMOND, Va., July 9, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announces a business update encompassing the...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Newsfile
09.07.2024
ISIN: NL0011832936
Cosmo Pharmaceuticals NV
COPN
LISTED
SIX
Invitation to Cosmo's Half-Year 2024 Webcast on 24 July 2024
Article
News Preview
Dublin, Ireland--(Newsfile Corp. - July 9, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it will publish its Half-Year 2024 results on Wednesday, 24 July 2024 at 07:00 am CEST. Cosmo invites investors, financial analysts and business/life science journalists to a live vi...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
08.07.2024
ISIN: FR0010417345
Dbv Technologies SA
DBV
LISTED
EURONEXT
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Article
News Preview
AMF Regulated InformationMontrouge, France, July 8, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.07.2024
ISIN: NL0012169213
Qiagen NV
QGEN
LISTED
NYSE
QIAGEN verbessert die Identifizierung menschlicher Überreste von Indigenen und Afroamerikanern
Article
News Preview
Partnerschaft mit der University of Montana treibt Anwendung von Next-Generation-Sequencing und forensischer genetischer Genealogie zur Identifizierung menschlicher Überreste voran // QIAGEN unterstützt den Aufbau der ersten von Indigenen geführten DNA-Datenbank und die Identifizierung menschlicher Überreste von Afroamerikanern mit Instrumenten, Ki...
Themefolio
Profiler
Peergroup
© Newsfile
08.07.2024
ISIN: CA23256X4075
Cybin Inc.
HELP
LISTED
NASDAQ
A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update
Article
News Preview
Miami, Florida--(Newsfile Corp. - July 8, 2024) - Fast-moving sectors need equally fast-moving companies, a box that Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) checks, supported by a June 26th update on progress made in fiscal 2024 ending on March 31st. In its presser, Cybin highlighted key advancements that strengthened its position as a lea...
Themefolio
Profiler
Peergroup
© PR Newswire
08.07.2024
ISIN: DE0006599905
Merck KGaA
MRK
LISTED
XETR
ASNA and Athinia® collaborate to boost semiconductor manufacturing yields through improved data sharing and traceability of subcomponent parts
Article
News Preview
CAMBRIDGE, Mass., July 8, 2024 /PRNewswire/ -- Today Athinia® announced a collaboration with ASNA to combine unprecedented data sharing and traceability to improve critical semiconductor component and subcomponent innovation. In today's fiercely competitive semiconductor landscape, the quality and reliability of components and subcomponents are p...
Themefolio
Profiler
Peergroup
© EQS Newswire
08.07.2024
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Just – Evotec Biologics erweitert Tech-Partnerschaft für Biosimilars mit Sandoz
Article
News Preview
  Just – Evotec Biologics erweitert Partnerschaft mit Sandoz für Entwicklung und kommerzielle Herstellung von Biosimilars Sandoz-Entwicklungspipeline wird potenziell um weitere Biosimilars erweitert Weitere Garantien für Sandoz langfristige Liefersicherheit für Biosimilars   Hamburg, Deutschland und Seattle, USA, 08. Juli 2024......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.07.2024
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz
Article
News Preview
  Just – Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Further guarantees for Sandoz long-term commercial supply security   Hamburg, Germany, and Seattle, WA, USA, 8 July 2024: Evotec SE ......
Themefolio
Profiler
Peergroup
© Newsfile
05.07.2024
ISIN: NL0011832936
Cosmo Pharmaceuticals NV
COPN
LISTED
SIX
Cosmo Shareholders Approved All Resolutions Proposed by the Board of Directors at Extraordinary General Meeting
Article
News Preview
Shareholders approved a dividend distribution of € 2.00 per ordinary share; representing an increase of 90% versus last year Shareholders approved all other proposals of the Board of Directors, including the adoption of the FY2023 annual accounts and updates to the remuneration policy of the Company...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.07.2024
ISIN: DK0060055861
Chemometec A/S
CHEMM
LISTED
CPH
Major shareholder announcement – BlackRock, Inc.
Article
News Preview
4 July 2024...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
03.07.2024
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
Article
News Preview
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.07.2024
ISIN: US83086J2006
Skye Bioscience Inc
SKYE
LISTED
NASDAQ
Skye Bioscience Appoints Dr. Karen Smith to Board of Directors
Article
News Preview
Seasoned industry veteran adds significant global biotech and biopharma experience to Skye’s Board of Directors Seasoned industry veteran adds significant global biotech and biopharma experience to Skye’s Board of Directors...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2024
ISIN: IE000LK2BOB4
Mural Oncology PLC
MURA
LISTED
NASDAQ
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Article
News Preview
WALTHAM, Mass. and DUBLIN, July 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on July 1, the Company granted to four newly h...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2024
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Article
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© EQS Newswire
02.07.2024
ISIN: DE0007165607
Sartorius AG
SRT
LISTED
XETRA
Joachim Kreuzburg strebt nach mehr als 20 Jahren als Vorstandsvorsitzender keine weitere Amtszeit an – Aufsichtsrat äußert großes Bedauern
Article
News Preview
Göttingen, 2. Juli 2024 Sartorius AG: Joachim Kreuzburg strebt nach mehr als 20 Jahren als Vorstandsvorsitzender keine weitere Amtszeit an – Aufsichtsrat äußert großes Bedauern Der langjährige Vorstandsvorsitzende der Sartorius AG, Dr. Joachim Kreuzburg, hat den Aufsichtsrat des Unternehmens darüber informiert, dass er nach mehr als 20 Jahren als C......
Themefolio
Profiler
Peergroup
© EQS Newswire
02.07.2024
ISIN: DE0007165607
Sartorius AG
SRT
LISTED
XETRA
After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office – Supervisory Board expresses great regret
Article
News Preview
  Göttingen, July 2, 2024 Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office – Supervisory Board expresses great regret The long-standing CEO of Sartorius AG, Dr. Joachim Kreuzburg, has informed the company's Supervisory Board that after more than 20 years as CEO of the company, he will not be s......
Themefolio
Profiler
Peergroup
© EQS Newswire
02.07.2024
ISIN: DE0007165607
Sartorius AG
SRT
LISTED
XETRA
Nach mehr als 20 Jahren als Vorstandsvorsitzender strebt Joachim Kreuzburg keine weitere Amtszeit an
Article
News Preview
Veröffentlichung einer Insiderinformation gemäß Artikel 17 MAR Sartorius AG: Nach mehr als 20 Jahren als Vorstandsvorsitzender strebt Joachim Kreuzburg keine weitere Amtszeit an Der langjährige Vorstandsvorsitzende der Sartorius AG, Dr. Joachim Kreuzburg, hat den Aufsichtsrat des Unternehmens darüber informiert, dass er nach mehr als 20 Jahren al......
Themefolio
Profiler
Peergroup
© EQS Newswire
02.07.2024
ISIN: DE0007165607
Sartorius AG
SRT
LISTED
XETRA
After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office
Article
News Preview
Disclosure of inside information according to Article 17 MAR Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office The long-standing CEO of Sartorius AG, Dr. Joachim Kreuzburg, has informed the company's Supervisory Board that, after more than 20 years as CEO, he will not be seeking another contr......
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2024
ISIN: DK0060055861
Chemometec A/S
CHEMM
LISTED
CPH
Preliminary revenue figures for the 2023/24 financial year
Article
News Preview
ANNOUNCEMENT NO. 270...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2024
ISIN: FI0009014377
Orion Oyj
ORNBV
LISTED
HEL
Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Article
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION1 JULY 2024 at 15:15 EEST...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2024
ISIN: FI0009014377
Orion Oyj
ORNBV
LISTED
HEL
Inside information: Orion upgrades full-year outlook for 2024
Article
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION1 JULY 2024 at 15:15 EEST...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2024
ISIN: US83086J2006
Skye Bioscience Inc
SKYE
LISTED
NASDAQ
Skye Bioscience Added to Russell 2000® and Russell 3000® Indexes
Article
News Preview
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced the Company has been included in the Russell 2000® Index and...
Themefolio
Profiler
Peergroup
© EQS Newswire
01.07.2024
ISIN: DE000A1MMCC8
Medios AG
ILM1
LISTED
XETR
Medios veranstaltet Symposium zum Thema „Versorgungssicherheit“
Article
News Preview
EQS-Media / 01.07.2024 / 09:32 CET/CEST PressemitteilungHauptstadtkongress 2024: Medios veranstaltet Symposium zum Thema „Versorgungssicherheit“ Berlin, 1. Juli 2024 – Die Medios AG, ein führender Anbieter von Specialty Pharma in Europa, war erstmalig auf dem Hauptstadtkongress in Berlin vertreten, der sich vom 26. bis zum 28. Juni 2024 dem L......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.07.2024
ISIN: DE000A1MMCC8
Medios AG
ILM1
LISTED
XETR
Medios hosts symposium on 'Security of supply”
Article
News Preview
EQS-Media / 01.07.2024 / 09:32 CET/CEST Press release“Hauptstadtkongress 2024”: Medios hosts symposium on "Security of supply” Berlin, July 01, 2024 – Medios AG, a leading provider of Specialty Pharma in Europe, was represented for the first time at the “Hauptstadtkongress” (Capital Congress) in Berlin, which took place from June 26 to June 2......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.07.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)
Article
News Preview
Press Release // July 01, 2024   Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)   Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) and its licensing partner Klinge Biopharma GmbH ("Klinge") jointly announce that the U.S. Food and Drug Administration ("FDA") approved FYB203/AHZA......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.07.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon erhält FDA-Zulassung für FYB203/AHZANTIVE®1) (Aflibercept-mrbb), ein Biosimilar für Eylea®2)
Article
News Preview
Pressemitteilung // 01. Juli 2024   Formycon erhält FDA-Zulassung für FYB203/AHZANTIVE®1) (Aflibercept-mrbb), ein Biosimilar für Eylea®2)   Planegg-Martinsried – Die Formycon AG (FWB: FYB, “Formycon“) und ihr Lizenzpartner Klinge Biopharma GmbH (“Klinge“) geben bekannt, dass die U.S. Food and Drug Administration (“FDA”) am 28. Juni 2024 die Zulas......
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2024
ISIN: DK0015998017
Bavarian Nordic A/S
BAVA
LISTED
CPH
Bavarian Nordic Converts Existing Credit Facility into Sustainability-linked Loan
Article
News Preview
COPENHAGEN, Denmark, July 1, 2024 – Bavarian Nordic today announced the conversion of its existing undrawn DKK 1 billion syndicated revolving credit facility (RCF) into a sustainability-linked loan (SLL)....
Themefolio
Profiler
Peergroup
© EQS Newswire
28.06.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
FDA erteilt Zulassung für Eylea®1)- Biosimilar FYB203/AHZANTIVE®2) (Aflibercept-mrbb)
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014 FDA erteilt Zulassung für Eylea®1)- Biosimilar FYB203/AHZANTIVE®2) (Aflibercept-mrbb) Planegg-Martinsried, Deutschland, 28. Juni 2024 – Die Formycon AG (FWB: FYB, "Formycon“) und ihr Lizenzpartner Klinge Biopharma GmbH ("Klinge") geben bekannt, dass die U.S......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.06.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
FDA erteilt Zulassung für Eylea®1)- Biosimilar FYB203/AHZANTIVE®2) (Aflibercept-mrbb)
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014 FDA erteilt Zulassung für Eylea®1)- Biosimilar FYB203/AHZANTIVE®2) (Aflibercept-mrbb) Planegg-Martinsried, Deutschland, 28. Juni 2024 – Die Formycon AG (FWB: FYB, "Formycon“) und ihr Lizenzpartner Klinge Biopharma GmbH ("Klinge") geben bekannt, dass die U.S......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.06.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
Article
News Preview
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014 FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb) Planegg-Martinsried, Germany, 28. June 2024 – Formycon AG (FSE: FYB, “Formycon”) and its licensing partner Klinge Biopharma GmbH ("Klinge") announce that the U.S. Food and D......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.06.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
Article
News Preview
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014 FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb) Planegg-Martinsried, Germany, 28. June 2024 – Formycon AG (FSE: FYB, “Formycon”) and its licensing partner Klinge Biopharma GmbH ("Klinge") announce that the U.S. Food and D......
Themefolio
Profiler
Peergroup
© Globe Newswire
28.06.2024
ISIN: DK0060257814
Zealand Pharma A/S
ZEAL
LISTED
CPH
Zealand Pharma major shareholder announcement: Van Herk Investments
Article
News Preview
Company announcement – No. 38 / 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.06.2024
ISIN: DK0060257814
Zealand Pharma A/S
ZEAL
LISTED
CPH
Total number of shares and voting rights in Zealand Pharma at June 28, 2024
Article
News Preview
Company announcement – No. 37 / 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.06.2024
ISIN: DK0015998017
Bavarian Nordic A/S
BAVA
LISTED
CPH
Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa
Article
News Preview
COPENHAGEN, Denmark, June 28, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced an extended commitment to help fight the current mpox outbreak in Africa. The Company’s MVA-BN vaccine, the only FDA and EMA-approved mpox vaccine, which served as an important tool during the 2022-2023 mpox outbreak, could soon also become available in the DR Cong...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.06.2024
ISIN: ES0167733015
Oryzon Genomics SA
ORY
LISTED
BME
ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders
Article
News Preview
MADRID and CAMBRIDGE, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, announced the voting results from its Annual General Meeting of Shareholders held today in Madrid....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.06.2024
ISIN: DK0060257814
Zealand Pharma A/S
ZEAL
LISTED
CPH
Zealand Pharma completes registration of capital increase
Article
News Preview
Company announcement – No. 36 / 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.06.2024
ISIN: DK0010272202
Genmab A/S
GMAB
LISTED
CPH
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
Article
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.06.2024
ISIN: DK0010272202
Genmab A/S
GMAB
LISTED
CPH
Completion of Share Buy-back Program
Article
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© EQS Newswire
27.06.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma continues growth path in the second quarter of fiscal year 2024
Article
News Preview
SCHOTT Pharma continues growth path in the second quarter of fiscal year 2024 Q2 2024 revenues up 11% yoy to EUR 247m at constant currencies Q2 2024 EBITDA margin of 27.0% at constant currencies Share of strong-margin high-value solutions (HVS) at 53% in the first half of FY 2024 Guidance for fiscal year 2024 confirmed SCHOTT Pharma, a pioneer ......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.06.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma continues growth path in the second quarter of fiscal year 2024
Article
News Preview
SCHOTT Pharma continues growth path in the second quarter of fiscal year 2024 Q2 2024 revenues up 11% yoy to EUR 247m at constant currencies Q2 2024 EBITDA margin of 27.0% at constant currencies Share of strong-margin high-value solutions (HVS) at 53% in the first half of FY 2024 Guidance for fiscal year 2024 confirmed SCHOTT Pharma, a pioneer ......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.06.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma setzt Wachstumskurs im zweiten Quartal des Geschäftsjahres 2024 fort
Article
News Preview
SCHOTT Pharma setzt Wachstumskurs im zweiten Quartal des Geschäftsjahres 2024 fort Q2 2024 Umsatzerlöse steigen währungsbereinigt um 11 % gegenüber Vorjahr auf 247 Mio. Euro Q2 2024 währungsbereinigte EBITDA-Marge von 27,0 % Umsatzanteil der margenstarken High-Value-Lösungen (HVS) bei 53 % in der ersten Hälfte des Geschäftsjahres 2024 Prognose......
Themefolio
Profiler
Peergroup
© Globe Newswire
27.06.2024
ISIN: US75629V1044
Recursion Pharmaceuticals Inc
RXRX
LISTED
NASDAQ
Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
Article
News Preview
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock at a price to the public of $6.5...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2024
ISIN: DK0010272202
Genmab A/S
GMAB
LISTED
CPH
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Article
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2024
ISIN: US75629V1044
Recursion Pharmaceuticals Inc
RXRX
LISTED
NASDAQ
Recursion Announces Proposed Offering of Class A Common Stock
Article
News Preview
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that it intends to offer and sell $200.0 million of shares of its Class A common stock in an underwritten public offering. All of...
Themefolio
Profiler
Peergroup
© EQS Newswire
26.06.2024
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Hauptversammlung der Eckert & Ziegler SE beschließt Abspaltung der Pentixapharm AG
Article
News Preview
Berlin, 26.06.2024. Die ordentliche Hauptversammlung der Eckert & Ziegler SE (ISIN DE0005659700) hat heute die Abspaltung der Pentixapharm AG von der Eckert & Ziegler SE und eine Dividendenausschüttung für das Geschäftsjahr 2023 in Höhe von EUR 0,05 je Aktie beschlossen. Wie bereits im Vorjahr fand die Hauptversammlung als Präsenzveranstal......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.06.2024
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Hauptversammlung der Eckert & Ziegler SE beschließt Abspaltung der Pentixapharm AG
Article
News Preview
Berlin, 26.06.2024. Die ordentliche Hauptversammlung der Eckert & Ziegler SE (ISIN DE0005659700) hat heute die Abspaltung der Pentixapharm AG von der Eckert & Ziegler SE und eine Dividendenausschüttung für das Geschäftsjahr 2023 in Höhe von EUR 0,05 je Aktie beschlossen. Wie bereits im Vorjahr fand die Hauptversammlung als Präsenzveranstal......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.06.2024
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Annual General Meeting of Eckert & Ziegler SE Approves Split-Off of Pentixapharm AG
Article
News Preview
Berlin, June 26, 2024. The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today resolved to split-off Pentixapharm AG from Eckert & Ziegler SE and to distribute a dividend of EUR 0.05 per share for the 2023 financial year. As in the previous year, the Annual General Meeting was held as an in-person event at Eckert & ......
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2024
ISIN: DK0060336014
Novozymes A/S
NSIS B
LISTED
CPH
Major shareholder announcement
Article
News Preview
Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis, that as of June 21, BlackRock, Inc. crossed the 5% threshold regarding issued share capital in Novozymes A/S, part of Novonesis Group....
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2024
ISIN: NL0015000DX5
Atai Life Sciences N.V.
ATAI
LISTED
NASDAQ
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
Article
News Preview
NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2024
ISIN: DK0015998017
Bavarian Nordic A/S
BAVA
LISTED
CPH
Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to EMA
Article
News Preview
COPENHAGEN, Denmark, June 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of the Company’s vaccine candidate for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and old...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2024
ISIN: GB0009223206
Smith & Nephew PLC
SN
LISTED
LSE
Smith+Nephew takes centre court sponsoring players competing at Wimbledon; global Sports Medicine technology leader helping athletes get back in the game
Article
News Preview
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will sponsor tennis players participating in The Championships, Wimbledon 2024 to spotlight its advanced Sports Medicine portfolio alongside some of the greatest athletes in the world. Smith+Nephew endeavours to help people live their ‘Life Unlimited’ by aidi...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2024
ISIN: DK0060257814
Zealand Pharma A/S
ZEAL
LISTED
CPH
Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion
Article
News Preview
Company announcement – No. 35 / 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2024
ISIN: DK0060257814
Zealand Pharma A/S
ZEAL
LISTED
CPH
Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion
Article
News Preview
Company announcement – No. 34 / 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2024
ISIN: DK0060257814
Zealand Pharma A/S
ZEAL
LISTED
CPH
Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion
Article
News Preview
Company announcement – No. 33 / 2024...
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2024
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Eckert & Ziegler Tochter Pentixapharm erhält positive Rückmeldung der FDA zum Start einer Phase-III-Studie mit PentixaFor als radiopharmazeutisches Diagnostikum für primären Aldosteronismus
Article
News Preview
Würzburg/Berlin, 25.06.2024. Die Pentixapharm AG, ein Unternehmen, das Radiopharmazeutika entwickelt und sich zu 100% im Besitz der Eckert & Ziegler SE befindet, gab heute bekannt, dass es nach einem kürzlich stattgefundenen Type-C-Meeting mit der amerikanischen Gesundheitsbehörde FDA (Food and Drug Administration) eine positive Rückmeldung erh......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2024
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Eckert & Ziegler Tochter Pentixapharm erhält positive Rückmeldung der FDA zum Start einer Phase-III-Studie mit PentixaFor als radiopharmazeutisches Diagnostikum für primären Aldosteronismus
Article
News Preview
Würzburg/Berlin, 25.06.2024. Die Pentixapharm AG, ein Unternehmen, das Radiopharmazeutika entwickelt und sich zu 100% im Besitz der Eckert & Ziegler SE befindet, gab heute bekannt, dass es nach einem kürzlich stattgefundenen Type-C-Meeting mit der amerikanischen Gesundheitsbehörde FDA (Food and Drug Administration) eine positive Rückmeldung erh......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2024
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism
Article
News Preview
Würzburg/Berlin, Germany, 25 June 2024. Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler SE, today announced that it has received encouraging feedback from the U.S. Food and Drug Administration (FDA) following a recent Type C meeting with the Agency to directly proceed into a pivotal phase III registra......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2024
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism
Article
News Preview
Würzburg/Berlin, Germany, 25 June 2024. Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler SE, today announced that it has received encouraging feedback from the U.S. Food and Drug Administration (FDA) following a recent Type C meeting with the Agency to directly proceed into a pivotal phase III registra......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Friday, 23.01.2026, Calendar Week 04, 23rd day of the year, 342 days remaining until EoY.